For media inquiries, please contact Erich Horsley at: media@samumed.com

2020

Date	Title
Dec 01	Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology
Nov 17	Samumed Chief Medical Officer, Dr. Yusuf Yazici, Discusses Lorecivivint on the Podcast “ACR on Air”
Jun 01	Michael White, Ph.D. joins Samumed as Chief Scientific Officer
May 22	Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
Jan 23	Rheumatology Advisor: Effect of Intra-Articular Treatment on Patient-Reported Outcomes in Knee Osteoarthritis
Jan 21	BioSpace: Getting to the Root of the Disease: Developing Drugs Against the Hard-to-Target Wnt Pathway
Jan 06	DDNews: Meeting a new mechanism

2019

Date	Title
Nov 27	Healio Rheumatology: Lorecivivint yields improved patient-reported outcome scores in knee OA
Nov 14	HCPLive: Lorecivivint a Potential Novel Treatment for Knee Osteoarthritis
Nov 13	Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Oct 02	Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors
Sep 12	DDNews: A strong showing for SM07883
Aug 15	FierceBiotech: In Conversation with Samumed CEO Osman Kibar: Drugging Wnt, Restoring Youth and Unconventional Capital
Aug 14	Xtalks: Tackling Multiple Pathways with One Alzheimer’s Drug
Aug 05	Technology Networks: Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Jul 24	Alzheimer's News Today: Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
Jul 18	Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease
Jun 19	Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis
May 02	Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10	Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 10	Alzheimer's News Today: Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
Apr 04	Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
Mar 27	The Rheumatologist: SM04690 Promising for Knee OA